Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis
Ryan L. Crass, Tamara Al Naimi, Bo Wen, Ernane Souza, Susan Murray, Manjunath P. Pai, Shijing Jia
Abstract
). Although body weight was observed to influence the volume of distribution, a fixed dose of 75 mg every 12 h was predicted to achieve the target steady-state exposure. Neurotoxicities were reported in all patients, with acute kidney injury events in two patients. These events resolved within 2 to 4 days after discontinuing polymyxin B. Fixed maintenance dosing of polymyxin B without loading is predicted to achieve the targeted therapeutic exposure in CF adults. Treatment-limiting neurotoxicities are very common in this population.
Topics & Concepts
Polymyxin BPharmacokineticsDosingMedicineVolume of distributionCystic fibrosisNONMEMPolymyxinLiterPopulationPharmacologyAntibioticsGastroenterologyInternal medicineMicrobiologyBiologyEnvironmental healthAntibiotics Pharmacokinetics and EfficacyAntibiotic Resistance in BacteriaEpilepsy research and treatment